Literature DB >> 11584872

The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes.

H M Pettinati1.   

Abstract

The usefulness of selective serotonin reuptake inhibitors (SSRIs) to treat alcohol dependence continues to be a subject of debate. Most recently, investigations have tried to predict whether a given patient will respond to SSRIs in terms of reducing excessive alcohol drinking. The subtyping of alcohol-dependent individuals has ranged from relatively simple classifications (e.g., presence of comorbid depression) to more complex classifications (e.g., potential to have abnormalities in serotonin [5-HT] neurotransmission). Although only a few studies have been completed, results thus far indicate that alcoholic subgroups are differentially responsive to 5-HT pharmacotherapy with respect to drinking-related outcomes. In addition, there are preliminary results encouraging the use of SSRIs in combination with other medications for treating alcohol dependence in patients with and without comorbid psychiatric disorders. Information from these studies is promising, suggesting the need for further investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584872

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  24 in total

1.  Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food.

Authors:  Brett C Ginsburg; Richard J Lamb
Journal:  Alcohol Clin Exp Res       Date:  2014-03       Impact factor: 3.455

Review 2.  Suicide in alcohol-dependent individuals: epidemiology and management.

Authors:  Sami P Pirkola; Kirsi Suominen; Erkki T Isometsä
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Fluvoxamine effects on concurrent ethanol- and food-maintained behaviors.

Authors:  Brett C Ginsburg; R J Lamb
Journal:  Exp Clin Psychopharmacol       Date:  2006-11       Impact factor: 3.157

Review 4.  Pathological gambling: an update on neuropathophysiology and pharmacotherapy.

Authors:  Iulian Iancu; Katherine Lowengrub; Yael Dembinsky; Moshe Kotler; Pinhas N Dannon
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Effects of chronic fluvoxamine on ethanol- and food-maintained behaviors.

Authors:  Brett C Ginsburg; R J Lamb
Journal:  Life Sci       Date:  2006-04-07       Impact factor: 5.037

Review 6.  Current status of co-occurring mood and substance use disorders: a new therapeutic target.

Authors:  Helen M Pettinati; Charles P O'Brien; William D Dundon
Journal:  Am J Psychiatry       Date:  2013-01       Impact factor: 18.112

7.  Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.

Authors:  John D Roache; Yanmei Wang; Nassima Ait-Daoud; Bankole A Johnson
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

8.  [Combination treatment with SSRI and cognitive behavior therapy for relapse prevention of alcohol-dependent men. Results of a randomized, controlled multicenter therapeutic study].

Authors:  M Hautzinger; H Wetzel; A Szegedi; A Scheurich; B Lörch; P Singer; D Schläfke; H Sittinger; T Wobrock; M J Müller; I Anghelescu
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

Review 9.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Subtyping women with bulimia nervosa along dietary and negative affect dimensions: further evidence of reliability and validity.

Authors:  Eric Stice; Cara Bohon; C Nathan Marti; Kathryn Fischer
Journal:  J Consult Clin Psychol       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.